NANTES, France, Aug. 24, 2021 (GLOBE NEWSWIRE) — OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) today announced that the Company will be present at the following investor events: H.C. Wainwright 23rd Annual Global Investment Conference – September 13 – 15, 2021 – Hybrid conferenceAmsterdam MidCap Event – September 20, 2021 – Full digital eventInvestor Access Event – September 27 – 28, 2021 – ParisHealthTech Innovation Days – October 4 – 5, 2021 – ParisPortzamparc Biotech Health Conference – October 5, 2021 – ParisEuropean MidCap Event – October 21 – 22, 2021Geneva MidCap Event – December 1 – 2, 2021 Save the date OSE Immunotherapeutics will host a physical (Paris) and virtual “Immuno-oncology R&D Day” on October 12, 2021. The event will highlight OSE’s leading scientific role in immuno-oncology and its emerging proprietary portfolio, provide a more in-depth look at lead projects, Tedopi® and BI 765063, and their commercial potential. ABOUT OSE Immunotherapeutics OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases. The company’s immunology research and development platform is focused on three areas: T-cell-based vaccination, Immuno-Oncology (focus on myeloid targets), Auto-immunity & Inflammation. Its balanced first-in-class clinical and preclinical portfolio has a diversified risk profile: Vaccine platform Tedopi® (innovative combination of neoepitopes): the company’s most advanced product; positive results for Step-1 of the Phase 3 trial (Atalante 1) in Non-Small Cell Lung Cancer post checkpoint inhibitor failure.In Phase 2 in pancreatic cancer (TEDOPaM), sponsor GERCOR.In Phase 2 in ovary cancer, in combination with pembrolizumab (TEDOVA), sponsor ARCAGY-GINECO.In Phase 2 in non-small cell lung cancer in combination with nivolumab, sponsor Italian foundation FoRT.CoVepiT: a prophylactic second-generation vaccine against COVID-19, developed using SARS-CoV-2 optimized epitopes against multi variants. Positive preclinical and human ex vivo results. Voluntary and temporary Phase 1 enrollment suspension on-going (July 2021). Immuno-oncology platform BI 765063 (OSE-172, anti-SIRPα mAb on SIRPα/CD47 pathway): developed in partnership with Boehringer Ingelheim in advanced solid tumors; positive Phase 1 results in monotherapy and BI 765063 dose escalation study ongoing in combination with Ezabenlimab (PD-1 antagonist).CLEC-1 (novel myeloid checkpoint target): identification of mAb antagonists of CLEC-1 blocking the “Don’t Eat Me” signal that increase both tumor cell phagocytosis by macrophages and antigen capture by dendritic cells.BiCKI®: bispecific fusion protein platform built on the key backbone component anti-PD-1 (OSE-279) combined with new immunotherapy targets; 2nd generation of PD-(L)1 inhibitors to increase antitumor efficacity. Auto-immunity and inflammation platform FR104 (anti-CD28 monoclonal antibody): Licensing partnership agreement with Veloxis in the organ transplant market; ongoing Phase 1/2 in renal transplant (sponsored by the Nantes University Hospital); Phase 2-ready asset in an autoimmune disease indication.OSE-127/S95011 (humanized monoclonal antibody targeting IL-7 receptor): developed in partnership with Servier; positive Phase 1 results; in Phase 2 in ulcerative colitis (OSE sponsor) and an independent Phase 2a planned in Sjögren’s syndrome (Servier sponsor).OSE-230 (ChemR23 agonist mAb): first-in-class therapeutic agent with the potential to resolve chronic inflammation by driving affected tissues to tissue integrity. For more information: https://ose-immuno.com/en/ Click and follow us on Twitter and LinkedInhttps://twitter.com/OSEIMMUNOhttps://www.linkedin.com/company/10929673 Contacts OSE ImmunotherapeuticsMedia Sylvie DétryU.S. Media: LifeSci CommunicationsGuillaume van Renterghem – LifeSci Advisorssylvie.detry@ose-immuno.com Darren Opland, Ph.D.gvanrenterghem@lifesciadvisors.com +33 153 198 757darren@lifescicomms.com+41 76 735 01 31 +1 646 627 8387 Investor RelationsFrench Media: FP2COM Thomas GuillotFlorence Portejoie thomas.guillot@ose-immuno.com fportejoie@fp2com.fr +33 607 380 431+33 607 768 283 Forward-looking statementsThis press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics’ management in light of its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate. These forward-looking statements include statements typically using conditional and containing verbs such as “expect”, “anticipate”, “believe”, “target”, “plan”, or “estimate”, their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics’ shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on 15 April 2021, including the annual financial report for the fiscal year 2020, available on the OSE Immunotherapeutics’ website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements.